Aricept (Donepezil) is an acetylcholinesterase inhibitor, medication used in the treatment of dementia caused by mild to moderate Alzheimer’s disease. Aricept easily crosses the blood-brain barrier and stimulates the function of nerve cells in the brain and prevents the destruction of acetylcholine, a chemical substance in brain which low levels can impair the intellectual activity, the ability of people to think and memorize. The defects in cholinergic neurotransmission are suggested to be the cause of certain symptoms of Alzheimer's disease. Aricept improves cholinergic function. The medication has a potential to increase the concentration of acetylcholine by inhibition acetylcholinesterase which is known to lower the levels of acetylcholine. Aricept is a prescription medication, produced in the form of tablets: film-coated and extended release tablets prescribed for once daily use. The brand medication is manufactured by Eisai and Pfizer as a marketing and promoting partner.